Kezar Life Sciences, Inc.
NASDAQ:KZR
4.7 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 1.066 | 1.023 | 1.51 | 1.544 | 1.301 | 0.69 | 0.175 | 0.154 |
| Gross Profit
| 0 | 5.934 | -1.023 | -1.51 | -1.544 | -1.301 | -0.69 | -0.175 | -0.154 |
| Gross Profit Ratio
| 0 | 0.848 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 65.742 | 85.697 | 51.009 | 38.935 | 30.981 | 27.363 | 18.136 | 6.469 | 7.373 |
| General & Administrative Expenses
| 23.393 | 26.54 | 20.153 | 15.724 | 11.969 | 9.979 | 6.59 | 2.28 | 1.617 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 23.393 | 26.54 | 20.153 | 15.724 | 11.969 | 9.979 | 6.59 | 2.28 | 1.617 |
| Other Expenses
| 1.47 | 6.187 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 90.605 | 118.424 | 71.162 | 54.659 | 42.95 | 37.342 | 24.726 | 8.749 | 8.99 |
| Operating Income
| -90.605 | -105.237 | -71.162 | -54.659 | -42.95 | -37.342 | -24.726 | -8.749 | -8.99 |
| Operating Income Ratio
| 0 | -15.034 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 6.869 | 3.367 | 2.923 | 0.029 | 1.208 | 2.255 | 1.559 | 0.232 | 0 |
| Income Before Tax
| -83.736 | -101.87 | -68.239 | -54.63 | -41.742 | -35.087 | -23.167 | -8.517 | -8.99 |
| Income Before Tax Ratio
| 0 | -14.553 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -2.923 | -1.351 | -2.752 | -3.556 | 1.559 | 0 | 0 |
| Net Income
| -83.736 | -101.87 | -65.316 | -53.279 | -38.99 | -31.531 | -23.167 | -8.517 | -8.99 |
| Net Income Ratio
| 0 | -14.553 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.15 | -1.4 | -0.97 | -1.01 | -0.89 | -1.65 | -2.26 | -0.65 | -0.69 |
| EPS Diluted
| -1.15 | -1.4 | -0.97 | -1.01 | -0.89 | -1.65 | -2.26 | -0.65 | -0.69 |
| EBITDA
| -90.605 | -99.254 | -66.11 | -52.961 | -40.256 | -34.421 | -22.477 | -8.342 | -8.836 |
| EBITDA Ratio
| 0 | -14.179 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |